Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate‐to‐severe psoriasis: a pooled analysis of two randomized controlled trials-Reference-Cited by-同舟云学术

Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate‐to‐severe psoriasis: a pooled analysis of two randomized controlled trials

Published:2019-09-11 Issue:12 Volume:33 Page:2305-2312
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:J Eur Acad Dermatol Venereol

Author:

Blauvelt A.¹,Sofen H.²^ORCID,Papp K.³,Gooderham M.³⁴,Tyring S.⁵,Zhao Y.⁶,Lowry S.⁶,Mendelsohn A.⁶,Parno J.⁶,Reich K.⁷⁸

Affiliation:

1. Oregon Medical Research Center Portland OR USA

2. Department of Medicine (Dermatology) UCLA Los Angeles CA USA

3. Probity Medical Research Waterloo ON Canada

4. Skin Centre for Dermatology Peterborough ON Canada

5. Department of Dermatology University of Texas Health Science Center Houston TX USA

6. Sun Pharmaceuticals Princeton NJ USA

7. Translational Research in Inflammatory Skin Diseases Institute for Health Services Research in Dermatology and Nursing University Medical Center Hamburg‐Eppendorf Skinflammation^® Center Hamburg Germany

8. Dermatologikum Berlin Berlin Germany

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.15862

Reference17 articles.

1. Immunology of Psoriasis

2. Psoriasis: from Pathogenesis to Targeted Therapies

3. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics

4. Increased prevalence of psychiatric disorders and health care‐associated costs among patients with moderate‐to‐severe psoriasis;Han C;J Drugs Dermatol,2011

5. Consensus Guidelines for the Management of Plaque Psoriasis

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Understanding Barriers Impacting upon Patient Wellbeing: A Nationwide Italian Survey and Expert Opinion of Dermatologists Treating Patients with Moderate-to-Severe Psoriasis;Journal of Clinical Medicine;2023-12-24

2. Entwicklung der Patientencharakteristika und der Wirksamkeit der Biologika‐Therapie bei Patienten des Österreichischen Psoriasis‐Registers von 2004 bis 2022;JDDG: Journal der Deutschen Dermatologischen Gesellschaft;2023-12

3. Evolution of characteristics and biologic treatment effectiveness in patients of the Austrian psoriasis registry from 2004–2022;JDDG: Journal der Deutschen Dermatologischen Gesellschaft;2023-10-31

4. Targeting IL-1 controls refractory Pityriasis rubra pilaris;2023-10-13

5. Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real‐world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group;Journal of the European Academy of Dermatology and Venereology;2023-09